Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
Stock Summary
Top Correlated Resources
002393.SZ
Top 10 Correlated ETFs
002393.SZ
Top 10 Correlated Stocks
002393.SZ
Financial details
Company Rating
Buy
Market Cap
3.97B
Income
132.81M
Revenue
1.12B
Book val./share
24.29
Cash/share
9.01
Dividend
0.3
Dividend %
1.38%
Employees
1.48K
Optionable
No
Shortable
Yes
Earnings
28 Apr 2021
P/E
30.21
Forward P/E
-
PEG
0.22
P/S
3.54
P/B
0.9
P/C
2.41
P/FCF
17.36
Quick Ratio
2.37
Current Ratio
3.46
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
0.73
EPS next Y
-
EPS next Q
-
EPS this Y
1240%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
0.92%
Revenue last 5Y
1.19%
Revenue Q/Q
0.59%
EPS Q/Q
-28.49%
-
-
-
-
SMA20
-5.56%
SMA50
-5.74%
SMA100
1.38%
Inst Own
-
Inst Trans
-
ROA
2%
ROE
3%
ROC
0.03%
Gross Margin
60%
Oper. Margin
10%
Profit Margin
12%
Payout
41%
Shs Outstand
182.46M
Shs Float
85.75M
-
-
-
-
Target Price
-
52W Range
17.8-27.65
52W High
-19.44%
52W Low
+27.94%
RSI
61.18
Rel Volume
2.74
Avg Volume
1.55M
Volume
4.25M
Perf Week
8.64%
Perf Month
2.69%
Perf Quarter
-4.86%
Perf Half Y
-8.03%
-
-
-
-
Beta
0.285897
-
-
Volatility
0.84%, 0.85%
Prev Close
10.02%
Price
21.75
Change
9.79%
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 5.64 | 8.21 | 8.84 | 6.62 | 5.99 | |
| Net income per share | 0.64 | 1.01 | 1.03 | 0.05 | 0.67 | |
| Operating cash flow per share | 0.98 | 0.89 | 1.47 | 0.44 | 1.08 | |
| Free cash flow per share | 0.71 | 0.32 | 0.97 | -0.14 | 0.59 | |
| Cash per share | 8.11 | 8.45 | 9.26 | 9.06 | 9.06 | |
| Book value per share | 16.87 | 17.54 | 24.18 | 24.97 | 24.2 | |
| Tangible book value per share | 16.01 | 16.61 | 23.31 | 24.11 | 23.41 | |
| Share holders equity per share | 16.87 | 17.54 | 24.18 | 24.97 | 24.2 | |
| Interest debt per share | 0.51 | 0.46 | 0.15 | 0.11 | 0.19 | |
| Market cap | 5.69B | 4B | 4.93B | 2.97B | 3.64B | |
| Enterprise value | 4.3B | 2.53B | 3.27B | 1.43B | 2.03B | |
| P/E ratio | 48.69 | 21.63 | 26.21 | 345 | 29.85 | |
| Price to sales ratio | 5.52 | 2.66 | 3.05 | 2.61 | 3.34 | |
| POCF ratio | 31.73 | 24.6 | 18.38 | 38.92 | 18.56 | |
| PFCF ratio | 44.04 | 68.69 | 27.73 | -122.34 | 33.72 | |
| P/B Ratio | 1.85 | 1.25 | 1.12 | 0.69 | 0.83 | |
| PTB ratio | 1.85 | 1.25 | 1.12 | 0.69 | 0.83 | |
| EV to sales | 4.17 | 1.69 | 2.02 | 1.25 | 1.86 | |
| Enterprise value over EBITDA | 22.52 | 9.34 | 11.71 | 15.06 | 10.26 | |
| EV to operating cash flow | 23.97 | 15.58 | 12.17 | 18.73 | 10.33 | |
| EV to free cash flow | 33.27 | 43.51 | 18.37 | -58.87 | 18.76 | |
| Earnings yield | 0.02 | 0.05 | 0.04 | 0 | 0.03 | |
| Free cash flow yield | 0.02 | 0.01 | 0.04 | -0.01 | 0.03 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.16 | 0.18 | 0.16 | 0.14 | 0.15 | |
| Net debt to EBITDA | -7.29 | -5.4 | -5.97 | -16.24 | -8.18 | |
| Current ratio | 3.58 | 3.36 | 3.73 | 4.46 | 4.27 | |
| Interest coverage | 27.81 | 65.23 | 144.19 | 109.6 | 427.18 | |
| Income quality | 1.53 | 0.88 | 1.43 | 8.86 | 1.61 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | |
| Payout ratio | 0.5 | 0.31 | 0.3 | 6.39 | 0.15 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | |
| Research and developement to revenue | 0.1 | 0.06 | 0.08 | 0.07 | 0.1 | |
| Intangibles to total assets | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | |
| Capex to operating cash flow | -0.28 | -0.64 | -0.34 | -1.32 | -0.45 | |
| Capex to revenue | -0.05 | -0.07 | -0.06 | -0.09 | -0.08 | |
| Capex to depreciation | -0.89 | -1.91 | -1.49 | -1.59 | -1.47 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 15.59 | 19.96 | 23.67 | 5.3 | 19.1 | |
| ROIC | 0.03 | 0.05 | 0.04 | 0.01 | 0.03 | |
| Return on tangible assets | 0.03 | 0.05 | 0.04 | 0 | 0.02 | |
| Graham Net | 5.54 | 5.37 | 5.34 | 5.57 | 5.41 | |
| Working capital | 1.5B | 1.62B | 1.75B | 1.74B | 1.8B | |
| Tangible asset value | 2.92B | 3.04B | 4.26B | 4.15B | 4.27B | |
| Net current asset value | 1.47B | 1.6B | 1.53B | 1.52B | 1.58B | |
| Invested capital | 0.03 | 0.03 | 0.01 | 0 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 138.82M | 119.83M | 120.55M | 128.3M | 109.39M | |
| Average inventory | 252.24M | 260.34M | 258.32M | 238.18M | 233.48M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 143.92 | 95.17 | 91.95 | 106.55 | 72.67 | |
| Days of inventory on hand | 256.63 | 241.41 | 226.99 | 197.8 | 183.73 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 2.54 | 3.84 | 3.97 | 3.43 | 5.02 | |
| Inventory turnover | 1.42 | 1.51 | 1.61 | 1.85 | 1.99 | |
| ROE | 0.04 | 0.06 | 0.04 | 0 | 0.03 | |
| Capex per share | -0.27 | -0.57 | -0.5 | -0.58 | -0.48 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.44 | 1.38 | 1.4 | 1.68 | 1.69 | |
| Net income per share | 0.14 | 0.2 | 0.13 | 0.23 | 0.16 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | -0.04 | 0.31 | 0.34 | 0.11 | 0.51 | |
| Cash per share | 8.61 | 8.85 | 9.06 | 9.14 | 9.01 | |
| Book value per share | 24.1 | 24.3 | 24.18 | 24.41 | 24.29 | |
| Tangible book value per share | 23.29 | 23.49 | 23.39 | 23.62 | 23.51 | |
| Share holders equity per share | 24.1 | 24.3 | 24.18 | 24.41 | 24.29 | |
| Interest debt per share | 0.1 | 0.04 | 0.19 | 0.23 | 0.28 | |
| Market cap | 3.37B | 3.46B | 3.94B | 4.35B | 3.87B | |
| Enterprise value | 1.9B | 1.94B | 2.32B | 2.73B | 2.28B | |
| P/E ratio | 33.41 | 23.71 | 40.41 | 25.95 | 32.26 | |
| Price to sales ratio | 12.97 | 13.92 | 15.38 | 14.21 | 12.56 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | -426.2 | 62.56 | 64.3 | 222.24 | 41.87 | |
| P/B Ratio | 0.78 | 0.79 | 0.89 | 0.98 | 0.87 | |
| PTB ratio | 0.78 | 0.79 | 0.89 | 0.98 | 0.87 | |
| EV to sales | 7.33 | 7.81 | 9.07 | 8.91 | 7.39 | |
| Enterprise value over EBITDA | 60.56 | 43.5 | 132.45 | 53.66 | 58.9 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | -240.95 | 35.09 | 37.92 | 139.31 | 24.64 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0 | 0.02 | 0.02 | 0 | 0.02 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.15 | 0.14 | 0.15 | 0.16 | 0.17 | |
| Net debt to EBITDA | -46.56 | -34.06 | -92.14 | -31.95 | -41.21 | |
| Current ratio | 4.38 | 4.77 | 4.27 | 4.1 | 3.46 | |
| Interest coverage | 118.16 | 79.71 | 348.14 | 708.49 | 103.04 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0.34 | 0 | 0 | |
| Sales general and administrative to revenue | -0.05 | 0.27 | -0.2 | 0.07 | -0.04 | |
| Research and developement to revenue | 0.13 | 0.08 | 0.1 | 0.08 | 0.13 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.1 | -0.08 | -0.08 | -0.04 | -0.01 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 8.71 | 10.52 | 8.53 | 11.24 | 9.48 | |
| ROIC | 0 | 0 | 0 | 0.01 | 0.01 | |
| Return on tangible assets | 0.01 | 0.01 | 0 | 0.01 | 0.01 | |
| Graham Net | 5.17 | 5.6 | 5.4 | 5.27 | 4.61 | |
| Working capital | 1.77B | 1.8B | 1.8B | 1.85B | 1.71B | |
| Tangible asset value | 4.2B | 4.24B | 4.27B | 4.31B | 4.29B | |
| Net current asset value | 1.55B | 1.58B | 1.58B | 1.63B | 1.48B | |
| Invested capital | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 104.65M | 94.15M | 91.97M | 93.45M | 89.45M | |
| Average inventory | 247.75M | 234.35M | 234.28M | 239.78M | 240.55M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 96.7 | 81.68 | 77.65 | 68.23 | 64.08 | |
| Days of inventory on hand | 213.44 | 197.13 | 196.31 | 175.05 | 180.99 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.93 | 1.1 | 1.16 | 1.32 | 1.4 | |
| Inventory turnover | 0.42 | 0.46 | 0.46 | 0.51 | 0.5 | |
| ROE | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Capex per share | -0.15 | -0.11 | -0.11 | -0.07 | -0.01 |
Frequently Asked Questions
What is Tianjin Lisheng Pharmaceutical Co.,Ltd. stock symbol ?
Tianjin Lisheng Pharmaceutical Co.,Ltd. is a CN stock and trading under the symbol 002393.SZ
What is Tianjin Lisheng Pharmaceutical Co.,Ltd. stock quote today ?
Tianjin Lisheng Pharmaceutical Co.,Ltd. stock price is $21.75 today.
Is Tianjin Lisheng Pharmaceutical Co.,Ltd. stock public?
Yes, Tianjin Lisheng Pharmaceutical Co.,Ltd. is a publicly traded company.
Company Profile
- Volume Average 1.55M
- Market Capitalization 3.97B
- Employee 1.48K
- Headquarters Tianjin,CN
- IPO Date 2010-04-23
-
Website
https://www.lishengpharma.com 
Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the production and sale of chemical medicines. The company offers tablets, hard capsules, dripping pills, freeze-dried powder injections, water injections, and bulk medicines, as well as intermediates, diagnostic reagents, biochemical reagents, and plastic bottles. It also exports its products. The company is based in Tianjin, China. Tianjin Lisheng Pharmaceutical Co.,Ltd. operates as a subsidiary of Tianjin Pharmaceutical Holdings Co., Ltd.
